Bardox Quiz For 2012 Gm Meeting

5 Questions | Total Attempts: 15

SettingsSettingsSettings
Please wait...
Bardox Quiz For 2012 Gm Meeting

Welcome to the GM Meeting! This quiz will test your knowledge of Global Pipeline Marketing at Abbott. Don't forget to show your Certificate of Completion to one of the GPM booth staffers to enter our iPad2 raffle. Meet Bardox Bonnie! Help her on her path to treatment for her CKD. Each question you answer correctly will keep her further away from dialysis.


Questions and Answers
  • 1. 
    Which of the following contribute to unmet need in the area of Chronic Kidney Disease?
    • A. 

      Significant growth in risk factors for CKD, including diabetes, hypertension and obesity

    • B. 

      Asymptomatic early disease followed by dramatic health and economic consequences including the need for dialysis or kidney transplant

    • C. 

      Little innovation and limited treatment options to slow the progression of disease

    • D. 

      Limited patient knowledge of or involvement in their disease

    • E. 

      Kidneys available for transplant are plentiful across all markets

  • 2. 
    Which of the following is NOT a key strategic imperative for the launch of bardoxolone methyl?
    • A. 

      Changing the physician paradigm to include measuring kidney function (eGFR) and treating with bardoxolone to slow disease progression

    • B. 

      Building a strong value proposition story to demonstrate the net cost savings bardoxolone can offer by allowing patients to delay or avoid dialysis

    • C. 

      Develop the CKD market by driving disease awareness, education and urgency for treatment

    • D. 

      Proving small incremental benefits over the existing, genericized treatments used as standard of care

  • 3. 
    Identify which of the following statements about BEACON, the Phase III clinical trial for bardoxolone are TRUE
    • A. 

      BEACON will enroll approximately 2,000 patients, with an option to expand

    • B. 

      BEACON is expected to take more than 5 years to complete

    • C. 

      BEACON will enroll patients at sites across the US, Europe, Canada and Australia

    • D. 

      BEACON is an event-driven trial that can support a strong bardoxolone HEOR story

  • 4. 
    Which of the following statements are true about clinic-administered hemodialysis and its effect on CKD patients?
    • A. 

      Patients are confined to a chair for 3 to 5 hours at a time, 3 or 4 times a week

    • B. 

      Patients on dialysis face risks of complication associated with vascular access and significantly increased risk of CV events in the first year after dialysis is initiated

    • C. 

      Patients routinely report feeling a post-dialysis washout or "hangover" the next day, with low blood pressure, headaches, fatigue, and nausea.

    • D. 

      Patients on dialysis may be briefly depressed, but because they know they will only be on it for a few weeks, depression does not last very long

  • 5. 
    What can areas and affiliates do to best prepare for the first launch of bardoxolone in late 2015?
    • A. 

      Assess organizational needs to prepare for launch in line with accelerated brand strategy

    • B. 

      Validate local treatment paradigms, epidemiology and market potential

    • C. 

      Participate the Global Pipeline Summit and other collaborations on an on-going basis

    • D. 

      All of the above

Back to Top Back to top